FDA approves new oral three-drug regimen for extensively drug-resistant TB

India, Aug. 15 -- The treatment involves pretomanid tablets in combination with bedaquiline and linezolid, collectively referred to as the BPaL regimen, and has an efficacy rate of 90 per cent

The US Food and Drug Administration (FDA) has approved new oral three-drug regimen for the extensively-drug resistant tuberculosis (XDR-TB), estimated to have a mortality rate of 60 per cent.

The treatment involves pretomanid tablets in combination with bedaquiline and linezolid, collectively referred to as the BPaL regimen, according to FDA's statement on August 14, 2019. It has an efficacy rate of 90 per cent.

Previously available drugs had a success rate of only 34 per cent for XDR-TB and 55 per cent for multi-drug resistant TB (MDR-TB) cases, a...